

PhenoScore: AI-based phenomics to quantify rare disease and genetic variation

Alexander J M Dingemans^{1,2}, Max Hinne², Kim M G Truijen¹, Lia Goltstein¹, Jeroen van Reeuwijk¹, Nicole de Leeuw¹, Janneke Schuurs-Hoeijmakers¹, Rolph Pfundt¹, Illja J Diets¹, Joery den Hoed³, Elke de Boer¹, Jet Coenen-van der Spek¹, Sandra Jansen⁴, Bregje W van Bon¹, Noraly Jonis¹, Charlotte Ockeloen¹, Anneke T Vulto-van Silfhout¹, Tjitske Kleefstra¹, David A Koolen¹, Hilde Van Esch⁵, Gholson J Lyon^{6,7}, Fowzan S Alkuraya⁸, Anita Rauch⁹, Ronit Marom¹⁰, Diana Baralle¹¹, Pleuntje J van der Sluijs¹², Gijs W E Santen¹², R Frank Kooy¹³, Marcel A J van Gerven², Lisenka E L M Vissers^{1*}, and Bert B A de Vries^{1*}

¹Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6500 HB, P.O. Box 9101, Nijmegen, the Netherlands.

²Department of Artificial Intelligence, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Thomas van Aquinostraat 4, 6525 GD Nijmegen, the Netherlands

³Language and Genetics Department, Max Planck Institute for Psycholinguistics, 6500 AH Nijmegen, the Netherlands

⁴Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

⁵Center for Human Genetics, University Hospitals Leuven, University of Leuven, Leuven, Belgium.

⁶Department of Human Genetics and George A. Jervis Clinic, Institute for Basic Research in Developmental Disabilities (IBR), Staten Island, New York, USA

⁷Biology PhD Program, The Graduate Center, The City University of New York, New York, United States of America

⁸Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

⁹Institute of Medical Genetics, University of Zurich, Schlieren, 8952, Zurich, Switzerland.

¹⁰Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.

¹¹Faculty of Medicine, University of Southampton, University Rd, Southampton, SO17 1BJ, UK

¹²Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands

¹³Department of Medical Genetics, University of Antwerp, Antwerp, Belgium.

*corresponding authors (both authors contributed equally):
Lisenka.Vissers@radboudumc.nl, Bert.deVries@radboudumc.nl

Abstract

While both molecular and phenotypic data are essential when interpreting genetic variants, prediction scores (CADD, PolyPhen, and SIFT) have focused on molecular details to evaluate pathogenicity — omitting phenotypic features. To unlock the full potential of phenotypic data, we developed PhenoScore: an open source, artificial intelligence-based phenomics framework. PhenoScore combines facial recognition technology with Human Phenotype Ontology (HPO) data analysis to quantify phenotypic similarity at both the level of individual patients as well as of cohorts. We prove PhenoScore’s ability to recognize distinct phenotypic entities by establishing recognizable phenotypes for 25 out of 26 investigated genetic syndromes against clinical features observed in individuals with other neurodevelopmental disorders. Moreover, PhenoScore was able to provide objective clinical evidence for two distinct *ADNP*-related phenotypes, that had already been established functionally, but not yet phenotypically. Hence, PhenoScore will not only be of use to unbiasedly quantify phenotypes to assist genomic variant interpretation at the individual level, such as for reclassifying variants of unknown clinical significance, but is also of importance for detailed genotype-phenotype studies.

Keywords: artificial intelligence, VUS, machine learning, personalized medicine, facial recognition, deep phenotyping

Statement of conflict of interest: there is no conflict of interest.

1 Introduction

2 A significant portion of individuals with clinically and genetically heterogeneous rare diseases, such
3 as neurodevelopmental disorders (NDD), has been molecularly diagnosed in the last decade using
4 whole-exome sequencing (WES) [1–4]. Clinical WES data interpretation relies on filtering and
5 prioritization for rare genetic variants in disease-gene panels, which are subsequently interpreted
6 in the context of the patient’s clinical presentation [5]. Whereas this strategy is essential to identify
7 the disease-causing variant(s), it is estimated that, depending on the number of genes included in
8 the panel, dozens of variants are prioritized as diagnostic noise [6] — and this number is expected
9 to rise even more in the coming years with technological innovations such as genome sequencing
10 finding their way into the diagnostic arena [7–9].

11 At the molecular level, several computational methods, such as MutationTaster [10], PolyPhen
12 [11], SIFT [12], CADD score [13], have been designed to predict variant pathogenicity. These tools
13 use diverse approaches, such as looking at the impact of the variant on protein structure (Muta-
14 tionTaster, PolyPhen), taking conservation into account (MutationTaster, PolyPhen, SIFT) — or
15 trying to incorporate multiple sources of genomic information (CADD score). At the phenotypic
16 level, headway has been made by introducing Human Phenotype Ontology (HPO), systematically
17 capturing the presence of features observed in individuals with rare diseases [14]. However, equiv-
18 alent to molecular tools, algorithms using these HPO data to quantify phenotypic HPO similarity
19 between individuals with genetic disorders would provide significant benefits to diagnose rare dis-
20 ease. Such a quantitative phenotypic score could for instance assist with the interpretation of
21 genetic variants of unknown clinical significance (VUS), which constitute 10-30% of all variants
22 clinically assessed [4, 15]. Reducing the number of VUSs is of essence since studies have shown that
23 not all individuals and families respond similarly to the result of a VUS test-result, and usually do
24 not fully comprehend its meaning [16, 17], potentially leading to frustration, and/or distress due
25 to the uncertainty involving a possible diagnosis and course of disease. Importantly, VUSs have
26 also been shown to inflict inappropriate medical decisions [18, 19].

27 Next to reclassifying VUSs, quantifying phenotypic HPO similarity at the cohort level could also
28 help to provide further steps towards personalized medicine by automatically recognizing distinct
29 phenotypic subtypes leading to more tailored clinical prognosis [20–22].

30 A branch of science that could assist in objectively quantifying phenotypic data is artificial in-
31 telligence (AI). AI has dramatically reformed the manner clinical data are processed and analyzed
32 in recent years, with the AI revolution in medicine starting in pathology and radiology [23–26]. In
33 genetics, these new techniques have been employed in assisted interpretation of genomic variants
34 [27–29] and combining molecular and phenotypic evaluations, mainly looking at methods to use
35 phenotypic data in HPO to automatically prioritize genetic variants [30–36]. Furthermore, ad-

36 vances in computer vision have led to the application of facial recognition technology in clinical
37 genetics [37–42]. Facial recognition is able to assist in the recognition of (neuro)developmental
38 syndromes, since the development of the brain and facial shape are closely linked [43–46] — and
39 therefore, it comes as no surprise that a significant part of genetic disorders have distinct facial
40 features [47]. However, not all genetic syndromes have a clear, recognizable facial gestalt, which
41 hinders methods solely looking at facial features. Moreover, a syndromic phenotype often includes
42 more than ‘just the face’. Whereas tools have previously looked at either combining molecular
43 data with either HPO, or alternatively, with facial features [1, 39], an important area has been left
44 unexplored, which combines the facial- and HPO data into an AI-framework to predict phenotypic
45 similarities without the need for genomic data input. Therefore, we developed PhenoScore: a next-
46 generation open-source phenomics framework combining facial recognition technology with clinical
47 features, quantitatively collected in Human Phenotype Ontology (HPO) from deep phenotyping.

48 2 Results

49 2.1 The PhenoScore framework

50 PhenoScore is a framework that currently consists of two modules: a component that extracts
51 the facial features from a 2D facial photograph and a second module that takes HPO-based phe-
52 notypic similarity into account (Figure 1). The AI-based framework joins these results in three
53 outputs: a Brier score and corresponding p -value, defining the individual’s clinical similarity to
54 the syndrome assessed; a facial heatmap, highlighting important facial features for the syndrome;
55 and, a visualization of the most important other (non-facial) clinical features. In the training
56 phase of PhenoScore, at first an age-, sex-, ethnicity- matched dysmorphic control is sampled from
57 our in-house database for every individual with the genetic syndrome of interest. Next, the facial
58 features are automatically extracted from the facial photographs for both affected individuals and
59 controls and the phenotypic HPO similarity is calculated (with several HPO terms and their child
60 terms first removed from the dataset, as these are either facial HPO terms to be processed by
61 the facial recognition module, or HPO terms that are deemed subjective and therefore at risk for
62 interobserver variability). A support vector machine (SVM), a widely used classification algorithm
63 in machine learning, is trained on these features, resulting in a trained classifier that can be used to
64 generate a score for individuals, suspected to have the syndrome of interest. If we are interested in
65 quantifying phenotypic (sub)groups, a permutation test is added during the training phase, deter-
66 mining whether the trained classifier performs better than random chance — providing evidence
67 whether the two groups are distinguishable by PhenoScore. Finally, to provide insight into what
68 PhenoScore is doing and to learn more about the investigated syndromes, explainable AI is incor-

69 porated into PhenoScore as well, using Local Interpretable Model-agnostic Explanations (LIME)
70 [48, 49]. LIME works by generating random perturbed input data and inspecting the change in
71 predictions, thereby obtaining data on the relative importance of each feature. By using LIME for
72 both the facial- and HPO data, PhenoScore can generate facial heatmaps and visualizations on
73 the most important clinical features.

74 2.2 Proof-of-Concept using PhenoScore for Koolen-de Vries syndrome

75 First, we investigated whether using our combined PhenoScore was actually an improvement on
76 solely using either facial- or phenotypic data. The SVM was trained on both separate feature sets
77 alone (e.g. HPO and facial features) and subsequently compared with the classification performance
78 of PhenoScore. To measure classification performance, the Brier score [50] was chosen as the
79 performance measure to focus on: it is defined as the mean squared difference between predicted
80 outcome and observed actual outcome (lower is better). Next to that, we also report the area
81 under the receiving operator curve (AUC; higher is better).

82 To demonstrate the power of the PhenoScore framework, we first performed a proof-of-concept
83 study using 63 individuals with Koolen-de Vries syndrome (KdVS, OMIM #610443, Figure 2),
84 caused by either proven pathogenic loss-of-function variants in *KANSL1* ($n=11$) or the 17q21.31
85 microdeletion ($n=52$). KdVS most prominent features reported in literature include hypotonia,
86 intellectual disability, and joint laxity [51–53], for which the interdependence in our modelling is
87 preserved using the graph structure of the HPO terms (Figure 2). Running Phenoscore on the 63
88 individuals with KdVS, we confirm the improvement on overall predictive performance when using
89 both facial and clinical features compared to using either one alone (Brier score 0.106 or AUC 0.92
90 for PhenoScore, in contrast to 0.130/0.90 when using only facial data and 0.121/0.90 when using
91 only phenotypic data, Table 1).

92 We next randomly excluded four individuals (facial images shown in Figure 2) from the train-
93 ing dataset and retrained PhenoScore, allowing us to test the performance of PhenoScore when
94 treating them as if diagnoses of KdVS were unknown. We then used PhenoScore to predict the sim-
95 ilarity of these four individuals when comparing them with 59 remaining individuals with KdVS in
96 the training set. PhenoScore output was displayed using LIME, providing heatmaps of prioritized
97 facial information according to PhenoScore (Figure 2). In addition, the most important clinical
98 features according to PhenoScore to be predictive for KdVS were summarized by numerically scor-
99 ing and ranking them. According to PhenoScore, the nose and eyes are the most important facial
100 parts when recognizing KdVS — while the presence of nevi, joint laxity, hypotonia, hypermetropia,
101 and EEG abnormalities are the clinical features of interest. This is completely consistent with ex-
102 pert opinion and the literature [51–53] and shows that the prediction is based on the extracted

103 facial features from 2D photos and phenotypic data in HPO — harnessing the power of both and
104 outperforms the separate predictions.

105 **2.3 Expanding PhenoScore to 26 syndromes**

106 After our proof-of-concept using KdVS, we next assessed the performance of PhenoScore for
107 the classification of other genetic syndromes too. Hereto, we selected 25 syndromes ([Table 1](#)
108 and Supplemental [Table 1](#)) including both clinically well-recognizable syndromes based on facial
109 gestalt, such as Kleefstra syndrome (OMIM #610253, caused by pathogenic variants in *EHMT1*),
110 Helsmoortel-van der Aa syndrome (OMIM #615873, caused by pathogenic variants in *ADNP*) and
111 Coffin-Siris syndrome (OMIM #135900, *ARID1B*), but also more recently identified syndromes for
112 which facial gestalt is less prominent, including IDDAM (OMIM #615032, *CHD8*) and IDDFBA
113 (OMIM #618089, *FBXO11*).

114 Analyzing all these syndromes, we demonstrate that PhenoScore is a statistically significant
115 improvement on using either feature set alone, and therefore, the whole is more than the sum of its
116 parts in this case (median Brier score 0.22 for facial features on the whole dataset, 0.16 for HPO
117 data and 0.15 for PhenoScore, $p < 0.001$; median AUC 0.71 for facial features, 0.85 for HPO data
118 and 0.87 for PhenoScore, $p < 0.001$, [Table 1](#)). Furthermore, our post hoc checks show that there
119 was no overfitting using the internal control dataset (see Supplemental [Table 2](#)).

120 For 25 of 26 syndromes (96%), PhenoScore was able to identify predictive features that char-
121 acterized these syndromes and recognized a distinct phenotypic entity ([Table 1](#)). As expected,
122 and visualized in the LIME heatmaps ([Figure 3](#)), these features corresponded remarkably well
123 with those described in the literature. For instance, for Helsmoortel-van der Aa syndrome (OMIM
124 #615873), the facial- and forehead regions are prioritized in the predictions, as seen in the gen-
125 erated heatmap ([Figure 3d](#)) — corresponding with the known dysmorphic characteristics for this
126 syndrome.

127 Moreover, for a genetic syndrome which lacks explicit facial features, like IDDAM, apparent
128 overgrowth symptoms, such as macrocephaly and tall stature, were identified as significant predic-
129 tors, while no relevant facial features were extracted, as displayed in the heatmap and summarized
130 ranking scores. A similar case is made for the genetic disorder associated with pathogenic variants
131 in *DYRK1A*: while the classifier based only on the facial features does not provide any meaningful
132 predictions, the addition of other phenotypic data in HPO did allow PhenoScore to distinguish
133 this syndrome as a phenotypic entity. These data suggest that PhenoScore objectively extracts,
134 distinguishes, and visualizes the specific clinical features for genetic syndromes and highlights that
135 the addition of non-facial phenotypic data in HPO is essential.

136 **2.4 PhenoScore is scalable as it requires only a low number of individ-** 137 **uals for training**

138 Most genetic disorders are individually rare, with sometimes only 3-5 individuals reported world-
139 wide. We therefore next investigated how many data sets PhenoScore requires for accurate clas-
140 sification of a specific syndrome. We checked the performance of PhenoScore while increasing the
141 number of individuals in the complete dataset of 26 genetic syndromes with the combination of
142 facial- and HPO features, starting with only 2 individuals. This analysis revealed that, with three
143 individuals to train on, the median classification performance for the investigated syndromes is
144 already clinically acceptable (AUC 0.85; [Figure 4](#)). The classification performance can be further
145 improved when the training sets increase in size (median AUC 0.90 with seven individuals, 0.95
146 for 17 individuals).

147 **2.5 Use case 1: Objective clinical quantification for the interpretation** 148 **of molecular VUS**

149 To display the power of PhenoScore in the clinical interpretation of variants at an individual
150 level, we reassessed reported VUSs (ACMG class 3) in the Radboudumc department of Human
151 Genetics. These individuals were not included in the training of PhenoScore and can therefore
152 be considered real out-of-sample cases. In total, we identified 15 individuals in whom a class 3
153 variant was reported in either of 11 of the 26 syndromes ([Supplemental Table 3](#)). PhenoScores
154 were calculated, and when using thresholds of ≤ 0.30 (for ‘no phenotypic match’) and ≥ 0.70 (for
155 ‘phenotypic match’), PhenoScore was able to classify 9/15 (60%) of the cases as either match ($n=2$)
156 or no match ($n=7$). The other 6 cases had an inconclusive PhenoScore result (scores >0.30 but
157 <0.70). Interestingly, for only 1/9 cases for which PhenoScore was conclusive, the clinician made
158 a decision for the VUS based on the phenotype — PhenoScore was essential for the other eight
159 cases. Importantly, parallel functional follow-up for 4 variants confirmed the PhenoScore outcome,
160 whereas for the remaining cases, functional follow-up was inconclusive.

161 **2.6 Use case 2: Next-generation phenomics for the generation of sophis-** 162 **ticated genotype-phenotype correlations**

163 Genotype-phenotype studies for rare diseases are often performed to gain insight into the clinical
164 spectrum, which allows clinicians to provide a more accurate counseling of individuals with rare
165 diseases. Molecularly, the toolkit to gain in-depth insight into aspects of pathogenicity is generally
166 applied in a research setting, and thus often not readily available for diagnostic follow-up. From a
167 clinical perspective, analyses are often limited to cluster analysis and/or principle component anal-

168 ysis, but without being able to determine what aspects clinically distinguish subtypes, if identified.
169 We tested whether PhenoScore can improve these hypothesis-driven approaches to distinguish, or
170 discover, clinical subtypes.

171 For two genetic syndromes in our dataset, i.e. *SATB1*-associated neurodevelopmental disorders
172 (OMIM #619228)[54], and Helsmoortel-Van Der Aa Syndrome (OMIM #615873, caused by dis-
173 ruption of *ADNP* [55]), it has previously been determined that there are (at least) two molecular
174 subtypes. For *SATB1*, it has also been acknowledged that individuals with missense variants and
175 those with loss-of-function variants, are clinically different. As proof-of-concept, PhenoScore con-
176 vincingly distinguished two groups for *SATB1* (Brier score 0.18, AUC 0.81, $p = 0.02$), confirming
177 the original results [54]. For *ADNP*, it was recently shown that individuals with pathogenic variants
178 in *ADNP* show one of two distinct methylation signatures (type 2, when variant affects position
179 between c.2000 and c.2340; or type 1, when the variant occurs outside of this interval), suggesting
180 the possibility of two syndromes associated with this gene [56]. Clinically, however, these individu-
181 als could not be conclusively distinguished [57]. Prior to determining PhenoScores, we categorized
182 the individuals as having either a type 1 or type 2 *ADNP* signature. Initially, we assessed the
183 performance of PhenoScore using only individuals ($n=33$) for whom both facial photographs and
184 clinical features were available, but failed to identify a statistically significant difference between
185 the groups (Brier 0.30, AUC 0.52, $p = 0.35$). However, using the *ADNP* Human Disease Gene
186 website, we could collect HPO-only data of more individuals. Using this dataset, we obtained clin-
187 ical features in HPO of 58 individuals (29 in each group), and on these data PhenoScore did show
188 evidence for two phenotypically different entities (Brier 0.24, AUC of 0.71, $p = 0.02$). Inspecting
189 the generated PhenoScore explanations for clinically relevant differences (Figure 5), it seems that
190 recurrent infections and gastrointestinal problems (reflux, constipation, feeding difficulties) are 2-3
191 times more common in type 2 than in type 1.

192 3 Discussion

193 PhenoScore provides a significant step in the advancement of AI in clinical genetics: a novel
194 machine learning phenomics framework unifying facial and phenotypic features using high-quality
195 data directly from affected individuals instead of generic phenotypic descriptions of a syndrome.
196 Others have introduced AI in this domain of healthcare, with for instance the application of using
197 HPO terms to prioritize genetic variants while comparing individuals to the known phenotype of
198 disorders in the literature [30, 31, 36, 58]. The utilization of facial recognition technology to assist
199 clinicians in diagnosing individuals has been successful too, with most, unfortunately, relying on
200 proprietary commercial algorithms [35, 37–42]. We now show a next step, with an open-source

201 framework that takes the complete phenotype into account, including both facial- and phenotypic
202 features directly from affected individuals, and uses AI to provide a score on how well the patient's
203 phenotype (as a whole) matches individuals with a known syndrome.

204 PhenoScore detected a recognizable phenotype in all but one investigated genetic syndrome
205 (25/26; 96%), and only needed as little as three individuals for classification performance. In this
206 manner, PhenoScore assists clinicians and molecular biologists in quantifying phenotypic similarity,
207 at both an individual- and group level for theoretically all OMIM-listed disorders. The sole disorder
208 for which PhenoScore failed to identify a phenotype was for variants in *ACTL6A*. Interestingly,
209 this is the only of 26 syndromes that has not been recognized by OMIM as a genetic disorder,
210 due to lack of (phenotypic) evidence in combination with the fact that individuals in whom the
211 *ACTL6A* variants were uncovered, had not been tested by trio whole exome sequencing. OMIM
212 therefore concluded that it is uncertain that the variants in *ACTL6A* cause the phenotype of these
213 individuals.

214 Assisting variant classification of VUSs is an obvious use-case for PhenoScore. Of course, several
215 *in vitro* functional assays are available to assess variant pathogenicity, but so far these are mostly
216 used for genes involved in oncogenetic disorders [59, 60]. For neurodevelopmental disorders, these
217 assays are scarce since they need to be developed on a gene-per-gene basis, and for these rare
218 disorders, this is usually not cost-effective and solely done for research purposes. Other methods
219 to assess genetic variants include protein structural analysis [61], which however still relies on
220 the availability of relevant protein structures. Our approach theoretically works for any (genetic)
221 condition with a recognizable phenotype, provided there are sufficient individuals for training the
222 algorithm, and that HPO data and 2D-facial photos are available. Indeed, PhenoScore is as good as
223 its input data. In the field of rare diseases, however, major efforts are put in obtaining these high-
224 quality quantitative phenotypic data, as for instance shown by collections of datasets by the Human
225 Disease Gene website series [62], GeneReviews, DECIPHER and OMIM [63–65]. Here, the use of
226 HPO terms, in combination with the use of Resnik scores (ensuring that the use of similar HPO
227 terms leads to comparable results), minimizes the effect of variation in clinical terminology used
228 between clinicians, and thus deriving the most benefits from the AI-based quantitative phenotypic
229 framework.

230 PhenoScore also helped to objectively obtain genotype-phenotype correlations, by training on
231 suspected phenotypic subgroups combined by permutation testing to quantify statistical signifi-
232 cance. We replicated earlier findings in *SATB1*, quantitatively underscoring that truncating vari-
233 ants lead to a significantly different phenotype than missense variants [54]. Whereas for *SATB1*
234 the different phenotypes were also subjectively identifiable from expert opinion, the power of
235 PhenoScore was shown by demonstrating the existence of two distinct phenotypes associated with

236 Helmsmoortel-van der Aa syndrome. Molecularly, two different methylation signatures have been
237 published, which were discriminated by the mutation location in *ADNP* [55–57]], but for which
238 clinically, no differences were observed. PhenoScore was not only able to prove the existence of
239 clinically distinctive groups, but also provided insight into which clinical features separates the two
240 clinical entities. For instance, neurodevelopmental problems are more common in the *ADNP*-type
241 1, while gastrointestinal symptoms, recurrent infections and short stature are 2-3 times more com-
242 mon in *ADNP*-type 2. These clinical features have a significant impact on an individual’s quality of
243 life, hence, by identifying these subgroups, PhenoScore directly impacted clinical recommendations
244 for these individuals and families.

245 These subgroup analyses could in theory be performed for every (genetic) syndrome caused
246 by different types of SNVs or CNVs — which is the case in a significant portion of the currently
247 ~1600 known NDD genes. While recognizing specific novel subgroups is a first step towards
248 personalized medicine and provides improved clinical prognosis and recommendations (as shown
249 for the subgroups in *ADNP* and *SATB1*), not finding a distinct difference is useful too: it helps to
250 assess whether two types of genetic variation have the same effect (i.e. whether missense variants
251 actually cause haploinsufficiency). Furthermore, PhenoScore could be utilized to find phenotypic
252 outliers, of whom the molecular mechanism leading to disease might be novel. By quantifying
253 the complete phenotypic similarity and visualizing differences between (sub)groups, PhenoScore
254 empowers detailed genotype-phenotype studies, leading to new insights on both the genetic- and
255 phenotypic level.

256 The discriminating clinical features for the two *ADNP*-related disorders were not represented in
257 a different facial gestalt, emphasizing the importance of adding HPO data across all organ systems.
258 In addition, given that these two phenotypic subgroups were not identified from more subjective
259 clinical analysis, using a predefined structured AI method of phenotypic data analysis provides
260 novel insights. To facilitate easy use in routine clinical care, it is, however, also of paramount
261 importance to be able to intuitively understand the AI output. We therefore also provided graphical
262 output such as facial heatmaps to visualize which (facial) features specified PhenoScore output.

263 Detailed genotype-phenotype analysis could in theory be performed for every (genetic) syn-
264 drome, suggesting that PhenoScore may be a valuable tool to also foster novel molecular insights.
265 That is, for many of the 1,600 known genes associated to an NDD phenotype, multiple types of
266 genetic variants (e.g. SNVs and CNVs) may cause the disorder. Whereas the molecular mecha-
267 nism for CNVs often relate to dosage-sensitivity, such as haploinsufficiency, the mechanisms for
268 SNVs leading to missense variants in those genes, are often less pertinent. PhenoScore may assess
269 phenotypic differences between individuals with the same syndrome, but caused by either CNVs
270 (‘group 1’) or missense variants (‘group 2’) and help to establish whether those missense variants

271 are also haploinsufficient. Similarly, PhenoScore could be utilized to find phenotypic outliers, of
272 which the molecular mechanism leading to disease might be novel.

273 In conclusion, PhenoScore bridges a gap between the fields of AI and Clinical Genetics by
274 quantifying phenotypic similarity, assisting not only in genetic variant interpretation, but also fa-
275 cilitating objective genotype-phenotype studies. We showcased its use for individuals with NDD,
276 whose phenotypes were captured using HPO. PhenoScore can, however, also easily be used be-
277 yond the field of rare disease, as adjustments to use other (graph-based) ontologies, such as for
278 instance SNOMED [66], can readily be integrated. The PhenoScore AI-based framework is thus
279 easily extended to other domains of (clinical) genetics, or even to completely different branches of
280 medicine, due to its open-source modular design.

281 4 Materials and Methods

282 4.1 Inclusion of individuals

283 The literature was searched for clinical studies which included facial photographs for 26 randomly
284 selected genetic syndromes associated with NDD. The photographs were collected and clinical
285 features, if available, were converted to HPO terms. Currently, PhenoScore is trained using data
286 of 501 non-familial individuals diagnosed with one of the 26 different genetic syndromes, collected
287 from 81 different publications (see Table 1 for the complete overview of the demographics per
288 genetic syndrome and Supplemental Table 1 for all publications used as sources for the data used
289 in this study). The phenotypic data were uploaded to the specific gene website in the HDG website
290 series [62] to ensure their public availability. The use of these data was approved by the ethical
291 committee of the Radboud university medical center (#2020-6151).

292 4.2 Data processing

293 To obtain a representative control group for our machine learning models, for each syndrome with n
294 individuals, n age-, sex- and ethnicity matched controls with a neurodevelopmental disorder seen at
295 our outpatient clinic at the Radboud university medical center were selected as described previously
296 [39] from our internal control database with over 1200 individuals with both facial image and
297 quantitative phenotypic data available (for a complete overview of the workflow of this study, please
298 see Figure 1). When no matched control was available, that particular individual was excluded from
299 our analysis. Next to that, when individuals were related to each other, one individual was chosen
300 (based on the quality of the picture) from that family. For each syndrome, cross-validation was
301 used to assess the performance of the classifiers. The number of folds during the cross-validation
302 procedure varied due to the considerable variation in dataset size: for every syndrome with at

303 least ten individuals, 5-fold cross-validation was used — otherwise, leave-one-out cross-validation
304 was chosen. As the selection of the randomly selected controls might significantly influence the
305 performance, for each genetic syndrome, different controls were sampled during ten random restarts
306 and the mean AUC and Brier scores of these ten iterations were noted. Furthermore, to confirm
307 the source of the data did not significantly influence our results, we did post hoc checks by using
308 not only the individuals from our internal control dataset, but the other included syndromes as
309 well as controls.

310 4.3 Extraction of facial features

311 The facial features were extracted using VGGFace2 [67, 68], a state-of-the-art facial recognition
312 method that utilizes a deep neural network. To avoid overfitting, we did not retrain VGGFace2,
313 but used its pretrained weights instead. The images were then processed by VGGFace2 and the
314 representation in the penultimate layer of the network was obtained. This representation was then
315 used as the facial feature vector. The process was performed as described previously: for the entire
316 (technological) methodology, please see [69].

317 4.4 Phenotypic similarity

318 To create a homogeneous dataset, the phenotype of every individual in this study was manually
319 converted into HPO terms [14]. A selection of HPO terms and all their child nodes were re-
320 moved to eliminate any subjectivity in assessing an individual. These were *Behavioral abnormality*
321 (*HP:0000708*), *Abnormality of the face* (*HP:0000271*), *Abnormal digit morphology* (*HP:0011297*),
322 *Abnormal ear morphology* (*HP:0031703*), *Abnormal eye morphology* (*HP:0012372*), and every node
323 which is a child node of either of these. We chose these terms as these are either facial features (to
324 be assessed by our facial recognition model) or are suspected to vary across clinicians doing the
325 assessment of an individual. In this manner, 3810 HPO terms were excluded with 12259 terms
326 remaining. To further reduce possible inter-observer variability, the phenotypic similarity between
327 individuals was calculated using the Resnik score [70], since it takes the semantic similarity between
328 symptoms into account. The Resnik score utilizes the information content (IC) of a symptom. In
329 an ontology akin to the HPO, the IC of a specific term can be seen as a measure of the rarity of a
330 term. Naturally, terms closer to the root of the HPO tree have a lower IC. For instance, *Abnormal-*
331 *ity of the nervous system* (*HP:0000707*) has an IC of 0.60. In contrast, *Focal impaired awareness*
332 *motor seizure with dystonia* (*HP:0032717*), significantly further down the HPO tree, has an IC
333 of 8.97. This corresponds to our intuition: rare features provide more information than common
334 features — since the prior probability of an individual reporting a rare symptom is, by definition,
335 smaller. The Resnik score uses this property by defining the similarity between two HPO terms as

336 the IC of their most informative (that is, with the highest IC) common ancestor in the HPO tree.
337 Since terms lower in the tree have a higher IC, the most informative common ancestor corresponds
338 to the last HPO term, which has both compared HPO terms as child nodes when traversing the
339 tree downwards. As an example: for the HPO terms *Reflex seizure (HP:0020207)* and *Focal motor*
340 *seizure (HP:0011153)*, the most informative common ancestor is *Seizure (HP:0001250)*, which has
341 an IC of 1.70. The Resnik similarity score for *Reflex seizure (HP:0020207)* and *Focal motor seizure*
342 *(HP:0011153)* is therefore 1.70. Next, we used the best-match average (BMA) to calculate the
343 similarity between two individuals (who usually report multiple HPO terms), in which the average
344 is taken over all best-matched pairwise semantic similarities, as previous studies determined it to
345 be most effective [71]. The idea is similar to that discussed above: if two individuals share a rare
346 symptom (*Focal impaired awareness motor seizure with dystonia (HP:0032717)*, for instance), they
347 are more similar than two individuals who only share a common symptom such as *Abnormality of*
348 *the nervous system (HP:0000707)*. The Resnik similarity score was calculated for every individual
349 and control and then averaged for both groups. In the end, this led to a $n \times 2$ matrix for the HPO
350 features: an average similarity score for each individual versus affected individuals and a score
351 for each individual versus the control group. We calculated the BMA Resnik score between the
352 individuals using the phenopy library in Python 3.8 [72].

353 4.5 Construction of machine learning model

354 Finally, the data were used to train a binary classifier. We selected a support vector machine
355 (SVM) as our classifier, known for its excellent overall performance in classification tasks. The
356 SVM was trained using the standard radial basis function kernel and a hyperparameter grid search
357 for C .

358 After determining the predictive performance of the model, we determined how many data the
359 classifier needed for an acceptable classification performance in clinical practice. Per syndrome,
360 we started with randomly selecting two individuals and two matched controls, training the model
361 on those, and using the rest of the individuals ($n - 2$, as one individual is used as training data)
362 and matched controls as a test set (two individuals that were not used in the first iteration as
363 the grid search in the SVM classifier needs at least two training samples). We ran ten random
364 restarts, randomly selecting another individual and matched control in each iteration. In each
365 restart, leave-one-out cross-validation was employed. The Brier score and AUC were noted and
366 averaged over the ten restarts. Next, the size of the training set was increased by one patient, and
367 one matched control, still using the rest of the individuals (now $n - 3$) and matched controls as
368 the test set. By increasing the training set by one individual and matched control each time and
369 recording the performance, the model's performance with an increasing number of individuals is

370 assessed.

371 The Wilcoxon signed-rank test was used to determine statistically significant differences in the
372 performance of the classifiers since it is a non-parametric test and, therefore, suitable — as these
373 data are not normally distributed.

374 **4.6 Explainability of predictions**

375 To see which features contained important information for our model, we generated Local Inter-
376 pretable Model-agnostic Explanations (LIME) [48, 49]. The main idea of this method is to train
377 a relatively simple local surrogate model to approximate the predictions of the model of interest.
378 Next, the original input data is perturbed, and the corresponding change in predictions is inspected
379 to obtain the relative importance of individual features. A key advantage of LIME is that it is
380 applicable to any model and can therefore be used directly on top of our pipeline.

381 When using LIME for image data, it is common practice to divide the image into several
382 segments, called superpixels. Therefore, we generated a raster of 25×25 pixel squares for each
383 facial image, randomly offset for each of 100 runs. Each pixel's relative importance was averaged
384 over these runs to obtain a higher resolution visualization of their significance. For the clinical
385 data, the original HPO features were perturbed to obtain the most significant ones in predictions.
386 In this case, LIME uses input data in which some HPO features are added and some are removed
387 from the input data, to see what the effect on the prediction is.

388 LIME explanations were generated for the individuals with the five highest predictions scores.
389 These explanations were then averaged, to obtain an overall explanation representative for that
390 specific genetic syndrome. To ensure only real important features were recovered, only HPO terms
391 that were identified in at least three individuals were used in this analysis.

392 **4.7 Hypothesis testing**

393 To see whether we could extend the use of our classifier to other applications than the reclassifi-
394 cation of VUSs, we designed a random permutation test for the performance of our model. This
395 enables the testing of a specific hypothesis for facial features, phenotypes, or both. An example
396 would be determining whether a newly discovered genetic syndrome consists of several (pheno-
397 typic/facial) subtypes. Using our framework, we trained a classifier on the labels of the suspected
398 subgroups. By performing a random permutation test, a p -value is calculated, so that the appear-
399 ance of the subgroups can be quantified. For a complete overview of the exact methodology of this
400 permutation test, please see the Supplemental Methods.

401 **Data and code availability**

402 The code of PhenoScore created during this study is freely available at
403 <https://github.com/ldingemans/PhenoScore>, to enable anyone to apply PhenoScore to their own
404 dataset. Included in PhenoScore are two examples: the data for the *SATB1* subgroups (positive
405 example) and random data (negative example). The used dataset in this study is not publicly
406 available due to both IRB and General Data Protection Regulation (EU GDPR) restrictions since
407 the data might be (partially) traceable. However, access to the data may be requested from the
408 data availability committee by contacting the corresponding author.

409 **Acknowledgements**

410 We are grateful to the Dutch Organisation for Health Research and Development: ZON-MW grants
411 912-12-109 (to B.B.A.d.V. and L.E.L.M.V.), Donders Junior researcher grant 2019 (B.B.A.d.V. and
412 L.E.L.M.V.) and Aspasia grant 015.014.066 (to L.E.L.M.V.). The aims of this study contribute
413 to the Solve-RD project (to L.E.L.M.V.), which has received funding from the European Union's
414 Horizon 2020 research and innovation program under grant agreement No 779257. R.F.K acknowl-
415 edges financial support of the Research Fund of the University of Antwerp (Methusalem-OEC
416 grant – “GENOMED”). The work of G.J.L. is supported by New York State Office for People
417 with Developmental Disabilities (OPWDD) and NIH NIGMS R35-GM-133408.

418 **Author information**

419 Conceptualization: A.J.M.D, M.H, L.E.L.M.V, B.B.A.d.V, M.A.J.v.G; Data curation: A.J.M.D,
420 K.M.G.T, L.G, J.v.R, N.d.L, J.S.H, R.P, I.J.D, E.d.B, J.d.H, J.v.d.S, S.J, B.W.v.B, N.J, A.T.V.v.S,
421 T.K, D.A.K, F.K, H.V.E, G.J.L, F.S.A, A.R, R.M, D.B, P.J.v.d.S., G.S, L.E.L.M.V, B.B.A.d.V;
422 Formal Analysis: A.J.M.D, M.H; Funding acquisition: L.E.L.M.V, B.B.A.d.V; Investigation: A.J.M.D,
423 M.H; Modelling: A.J.M.D, M.H.; Software development: A.J.M.D; Writing – original draft: A.J.M.D,
424 M.H, L.E.L.M.V, B.B.A.d.V, M.A.J.v.G; Writing – review and editing: all authors.

425 **Ethics declaration**

426 In this study, data from the Biobank ‘Intellectual Disability’, which is part of the Radboud Biobank
427 initiative (for more information, see [73] or [https://www.radboudumc.nl/en/research/radboud-
428 technology-centers/radboud-biobank](https://www.radboudumc.nl/en/research/radboud-technology-centers/radboud-biobank)) were used. Within this biobank, phenotypic and molecular
429 data have been systematically captured for individuals with (non-)syndromic ID referred to the

430 Radboud university medical center. The use of this dataset was approved by the ethical committee
431 of the Radboud university medical center (#2020-6151). Furthermore, the authors declare no
432 competing interests.




Figure 1: Here, the global workflow of this study is displayed, with the training and construction of PhenoScore on the left side. n individuals and n age-, sex- and ethnicity matched controls are selected for each syndrome. The facial features are extracted using a convolutional neural network, VGGFace2, and a support vector machine (SVM) is trained on these features. In parallel, the phenotypic similarity of individuals and controls is calculated, and a SVM is trained on those scores. Finally, a SVM is trained on both the facial features and the HPO similarity combined. On the right side of the figure, the trained classifier is used for a new individual with a VUS. Again, the phenotypic similarity and facial distances are calculated, and these are used as input for the trained SVM. The output is a score and assesses whether the individual of interest has that specific syndrome, thus the VUS being (likely) pathogenic.

Table 1: The number of individuals per genetic syndrome included in our analysis are shown here. For every individual, a facial photograph, phenotypic data, and an age-, sex- and ethnicity control with a neurodevelopmental disorder is available (otherwise, the individual was excluded). Per genetic syndrome, the sex distribution, the median age and the results of the support vector machine (SVM) classifier are displayed here. The Brier score, for which lower is better, per syndrome is shown — with the numbers shown corresponding to the mean of the scores during the ten iterations in which matched controls were sampled. For almost all syndromes, the combination of facial- and phenotypic data is an improvement over using either dataset alone. Furthermore, the last column of this table displays the calculated *p*-values for the investigated syndromes using the random permutation test. All but one are significant at the 0.05 (and 0.01) level, as expected when inspecting the classification results.

Gene/genetic syndrome	OMIM number	Number of individuals	Male/female (%)	Age (median in years)	Facial data only	HPO data only	PhenoScore	<i>p</i> -value
22q11 deletion syndrome	611867	19	10/9 (53%/47%)	5.0	0.189	0.146	0.124	<0.001
ACTL6A	NA	3	2/1 (67%/33%)	6.0	0.255	0.299	0.291	0.98
ADAT3 (NEDBGF)	615286	6	3/3 (50%/50%)	7.5	0.180	0.075	0.059	<0.001
ADNP (Helsmoortel-van der Aa syndrome)	615873	33	15/18 (45%/55%)	5.0	0.209	0.156	0.145	<0.001
ANKRD11 (KBG syndrome)	148050	22	15/7 (68%/32%)	9.5	0.236	0.196	0.180	<0.001
ARID1B (Coffin-Siris syndrome)	135900	34	16/18 (47%/53%)	6.0	0.155	0.087	0.070	<0.001
CHD3 (Snijders Blok-Campeau syndrome)	618205	27	11/16 (41%/59%)	10.0	0.216	0.148	0.144	<0.001
CHD8 (IDDAM)	615032	20	15/5 (75%/25%)	11.0	0.254	0.174	0.163	<0.001
DDX3X (MRXSSB)	300958	29	0/29 (0%/100%)	8.0	0.171	0.030	0.025	<0.001
DYRK1A (MRD7)	614104	13	7/6 (54%/46%)	12.0	0.258	0.192	0.174	<0.001
EHMT1 (Kleefstra syndrome)	610253	29	12/17 (41%/59%)	6.0	0.220	0.107	0.090	<0.001
FBXO11 (IDDFBA)	618089	18	14/4 (78%/22%)	7.0	0.265	0.250	0.247	<0.001
KANSL1 (Koolen-De Vries syndrome)	610443	63	28/35 (44%/56%)	6.0	0.130	0.121	0.106	<0.001
KDM3B (Diets-Jongmans syndrome)	618846	13	7/6 (54%/46%)	7.0	0.262	0.185	0.194	<0.001
MECP2 duplication (MRXSL)	300280	5	5/0 (100%/0%)	8.0	0.169	0.214	0.173	<0.001
MED13L (MRFACD)	616789	22	13/9 (59%/41%)	6.0	0.235	0.140	0.124	<0.001
PACS1 (Schuurs-Hoeijmakers syndrome)	615009	15	10/5 (67%/33%)	4.0	0.240	0.146	0.140	<0.001
PHIP (Chung-Jansen syndrome)	617991	16	9/7 (56%/44%)	12.0	0.236	0.274	0.242	<0.001
PPM1D (Jansen-de Vries syndrome)	617450	11	5/6 (45%/55%)	7.0	0.269	0.189	0.163	<0.001
PURA (NEDRIHF)	616158	33	18/15 (55%/45%)	9.0	0.232	0.126	0.110	<0.001
SATB1 (truncating, DEFDA)	619228	8	3/5 (38%/62%)	6.5	0.260	0.170	0.164	<0.001
SATB1 (missense, Kohlschütter-Tonz syndrome-like)	619229	11	5/6 (45%/55%)	11.0	0.123	0.231	0.229	<0.001
SON (ZTTK syndrome)	617140	25	13/12 (52%/48%)	6.0	0.234	0.133	0.123	<0.001
TRIO (MRD63)	618825	8	3/5 (38%/62%)	10.5	0.161	0.157	0.159	<0.001
WAC (DeSanto-Shinawi syndrome)	616708	9	3/6 (33%/67%)	4.0	0.185	0.204	0.176	<0.001
YY1 (Gabriele-de Vries syndrome)	617557	9	5/4 (56%/44%)	9.0	0.175	0.219	0.199	0.002




Figure 2: A) The HPO terms of all included individuals with Koolen-de Vries (KdVS) are shown here. HPO terms present in 20% or more of the individuals are annotated with text, and larger nodes correspond to a higher prevalence of that specific clinical feature. B) Four individuals diagnosed with Koolen-de Vries syndrome are presented here (written informed consent for the publication of these facial images was obtained). These were randomly selected from the included dataset without any selection criterion. C) For the four randomly selected individuals, three predictions are shown: using the facial image, using the phenotypic data, and finally, the PhenoScores, which combines both. Furthermore, heatmaps are generated using local interpretable model-agnostic explanations (LIME) to see which facial areas are most important according to our model, where blue correlates with KdVS and red areas correlate with controls. The nose and eyes are clearly prioritized, corresponding to the known dysmorphic features in Koolen-de Vries. Furthermore, the most important clinical features are shown for each individual and the contribution (corresponding to the LIME regression coefficient) of that feature to the prediction. D) Finally, a summarized heatmap was generated to investigate the overall most important facial and phenotypic features. We averaged the heatmaps of the five individuals with Koolen-de Vries with the highest prediction. Next to that, to obtain the most important clinical features, too, we averaged the LIME regression coefficient for the different symptoms of the five highest-scoring individuals based on HPO. Shown clinical features are ordered by importance, and the size of the circle indicates the relative importance of the feature.




Figure 3: The heatmaps and most important clinical features of all 26 genetic syndromes included in this study are displayed in this figure. The facial heatmaps are the average LIME heatmaps of the five individuals per genetic syndrome with the highest predictive score based on the facial data alone. For the phenotypic data, the positive LIME regression coefficients per symptom were averaged of the top-scoring five individuals based on the phenotypic data. The standard face used as background is a non-existent person generated using StyleGAN. [74].




Figure 4: The performance of the SVM using both facial- and HPO features with different sizes of the training set is shown here. Both the median Brier score and the median AUC improve if the number of individuals to train on is larger — as would be expected. Interestingly, only three individuals are needed for an already acceptable classification performance.




Figure 5: Above: a lollipop plot (generated using St. Jude’s ProteinPaint) of the genetic variants currently collected using the *ADNP* HDG website [62]. Of the 58 included individuals, 29 had a variant in the c.2000-2340 region, indicated by others as having a different methylation signature than variants outside this region [56]. Using only the HPO module of our PhenoScore framework, we first matched the groups on gender-, ethnicity- and age when possible to create two groups of the same size (29 vs. 29). We then trained a classifier on the two groups and found a significant difference (Brier score of 0.24, AUC of 0.71, $p = 0.01$). Below: the most important clinical features according to our model (determined using LIME) and the corresponding prevalence in both groups.

433 5 Supplementary data

434 5.1 Supplementary methods

435 5.1.1 Permutation test for hypothesis testing

436 To provide a p -value for our classification results and to enable the use of our framework for
437 the recognition of specific (sub)groups in genetic syndromes, we developed a permutation test —
438 inspired by the test described by Lopez-Paz & Oquab [75]. For every group of individuals of interest,
439 a group of age-, sex- and ethnicity-matched controls is sampled from our control database. We
440 extract the facial features using VGGFace2 and calculate the HPO similarity using the Resnik score,
441 after which a SVM is trained using cross-validation. A grid search for the optimal hyperparameters
442 is performed, and the Brier score is calculated for this combination of the group of individuals of
443 interest and the matched controls. This process is precisely the same as in our standard analysis.
444 Next, we randomly permute the labels (here, the labels correspond to whether an individual has the
445 syndrome or is a control) 100 times. We ensure that the number of positive and negative classes is
446 the same as in our original distribution of the labels. For each permutation, we repeat the process
447 of training a SVM to obtain a Brier score. We then perform a one-sided Mann-Whitney U test to
448 quantify the probability of the classification results being statistically significantly smaller (since
449 it is the Brier score we are comparing) than the randomly permuted scores.

450 To further strengthen our permutation test, we repeat the process five times in total, randomly
451 sampling matched controls from our database in each repetition. The five obtained p values were
452 then combined using Fisher's method [76] to gather a definitive p -value for this classification task
453 and, therefore, for this specific group of individuals of interest.

454 For the analyses for both *SATB1* and *ADNP*, we do not need to sample controls from our
455 database. However, these datasets are usually imbalanced, sometimes leading to problems for the
456 classifier. We therefore undersample the majority class to the size of the minority class by matching
457 the individuals on ethnicity, sex and age (in that order) and increase the number of permutations
458 of the labels to 1 000 (since we cannot repeatedly sample controls).

459 Finally, to have a negative control group for this test, we randomly sampled individuals from
460 our control database and calculated p -values for those. We did this for different cohort sizes ($n =$
461 3, 5, 10, 20 and 40) for in total 50 trials. Of those 50 trials, two resulted in a p -value smaller than
462 0.05 - exactly what would be expected by random chance in this number of trials. This shows that
463 our approach leads to the to-be-expected number of false alarms.

Supplementary table 1: A list is shown of the used publications per syndrome to create the dataset by extracting the phenotypic data and photographs of individuals in these papers. For several syndromes, not (yet) published individuals were added to the dataset, as indicated by Not published.

Genetic syndrome	PMID of used publications
22q11 deletion	15831592,17041934,18636631,1956057,21200182,25317860,3816857,12548732 [77-84]
ACTL6A	28649782 [85]
ADAT3	23620220,26842963 [86, 87]
ADNP	24531329,25217958,27031564,29724491 [55, 88-90]
ANKRD11	19920853,21527850,21654729,22307766,23494856,26269249 [91-96]
ARID1B	19034313,22405089,22426309,22585544,23906836,24569609,26395437,26754677,27112773,28323383,30055038,30349098,31981384,32339967 [97-110]
CHD3	30397230,32483341 [111, 112]
CHD8	23160955,24998929,31001818,31721432,Not published [113-116]
DDX3X	26235985 [117]
DYRK1A	18405873,21294719,23099646,23160955,25707398,Not published [113, 118-121]
EHMT1	22670141,Not published [122]
FBXO11	27479843,28343630 [123, 124]
KANSL1	16906164,17601928,18628315,21094706,22544363,26306646,Not published [51, 53, 125-128]
KDM3B	30929739 [129]
MECP2 duplication	18854860,18985075 [130, 131]
MED13L	23403903,24781760,25712080,28645799,29511999,29959045 [132-137]
PACS1	26842493 [138]
PHIP	29209020 [139]
PPM1D	28343630 [124]
PURA	27148565,29097605,29150892 [140-142]
SATB1 (missense + truncating)	33513338 [54]
SON	24896178,27256762,27545680 [4, 143-145]
TRIO	26721934,27418539 [146, 147]
WAC	23033978,26264232,26757981 [2, 148, 149]
YY1	21076407,28575647 [1, 150]

Supplementary table 2: The Brier scores of the support vector machine (SVM) classifier are displayed here, now with the other individuals included in this study as the control dataset, instead of the controls from the Radboud university medical center. The results are slightly worse than on the RUMC control dataset, as expected, since not for every individual, a control is available because the RUMC control dataset is significantly larger than the number of individuals included in this study.

Genetic syndrome	Facial data only	HPO data only	PhenoScore
22Q11	0.224	0.120	0.120
ACTL6A	0.248	0.231	0.219
ADAT3	0.165	0.073	0.067
ADNP	0.226	0.187	0.178
ANKRD11	0.253	0.148	0.146
ARID1B	0.175	0.100	0.091
CHD3	0.222	0.154	0.154
CHD8	0.239	0.160	0.126
DDX3X	0.226	0.022	0.024
DYRK1A	0.256	0.182	0.159
EHMT1	0.191	0.124	0.107
FBXO11	0.273	0.218	0.224
KANSL1	0.122	0.122	0.105
KDM3B	0.283	0.167	0.161
MECP2	0.167	0.252	0.199
MED13L	0.250	0.186	0.177
PACS1	0.277	0.197	0.198
PHIP	0.198	0.141	0.139
PPM1D	0.255	0.125	0.116
PURA	0.202	0.118	0.126
SATB1 (missense)	0.263	0.119	0.113
SATB1 (truncating)	0.137	0.205	0.186
SON	0.237	0.135	0.121
TRIO	0.132	0.178	0.173
WAC	0.137	0.193	0.171
YY1	0.260	0.294	0.274

Supplementary table 3: The 15 individuals with a VUS in one of the 26 included syndromes are displayed here, including the genetic information and the PhenoScore. For most, pathogenicity is still not clear at the time of writing, but for four, additional (genetic) testing has led to a change in pathogenicity class. The two *ARID1B* variants were both regarded as benign: one after methylation analysis (negative), the other variant since the individual was diagnosed with fragile X syndrome at a later stage. PhenoScore agrees with both assessments with a low prediction (0.03 and 0.02). Next to that, a splice variant in *CHD8* with a high PhenoScore of 0.89 was deemed pathogenic after RNA analysis was performed. Finally, a variant in *EHMT1* was deemed pathogenic after methylation analysis. This is the only variant in which PhenoScore disagrees with the outcome of a functional test, with a low score (0.06) – probably due to the phenotype not particularly matching.

Gene	Variant (genomic)	Variant (non) (coding)	Variant (RNA/protein)	Classification	Current status/comments	AUC PhenoScore this gene	PhenoScore this individual
ANKRD11	Chr16(GRCh37):g.89349673C>T	NM_001256182.1:c.3277G>A	p.(Gly1093Arg)	class 3	Variant unclear, clinician of opinion that phenotype fits	0.81	0.42
ANKRD11	Chr16(GRCh37):g.89349812..89349813delinsCA	NM_013275.5:c.3137..3138delinsTG	p.(Cys1046Leu)	class 3	Variant unclear	0.81	0.39
ANKRD11	Chr16(GRCh37):g.89347788G>A	NM_013275.5:c.5162C>T	p.(Thr1721Met)	class 3	Variant unclear, clinician of opinion that phenotype fits	0.81	0.65
ARID1B	Chr6(GRCh37):g.157406024C>G	NM_020732.3:c.2266C>G	p.(Pro756Ala)	class 3	Variant unclear, EpiSign analysis negative	0.96	0.03
ARID1B	Chr6(GRCh37):g.157488314C>T	NM_001346813.1:c.2981C>T	p.(Ser994Leu)	class 3	Other genetic diagnosis confirmed and no pictures available, only HPO	0.96	0.02
CHD8	Chr14(GRCh37):g.218701111C>G	NM_001170629.1:c.4062+5G>C	p.?	class 3	Pathogenic after RNA analysis	0.84	0.89
DDX3X	ChrX(GRCh37):g.41203603C>T	NM_001356.4(DDX3X):c.976C>T	p.(Arg326Cys)	class 3	Variant unclear, clinician of opinion that phenotype fits	0.99	0.02
DDX3X	ChrX(GRCh37):g.41205825T>C	NM_001356.4:c.1565T>C	p.(Ile522Thr)	class 3	Variant unclear	0.99	0.02
EHMT1	Chr9(GRCh37):g.140674167T>C	NM_024757.4:c.2273T>C	p.(Leu758Pro)	class 3	Pathogenic after EpiSign analysis	0.95	0.06
KDM3B	Chr5(GRCh37):g.137727707A>T	NM_016604.3:c.2386A>T	p.(Arg796Trp)	class 3	Variant unclear	0.78	0.36
PHIP	Chr6(GRCh37):g.79707136T>C	NM_017934.6:c.2196A>G	p.(Val732=)	class 3	Variant unclear	0.68	0.86
PPM1D	Chr17(GRCh37):g.58711260C>T	NM_003620.3:c.748C>T	p.(Arg250*)	class 3	Variant unclear	0.88	0.47
PURA	Chr5(GRCh37):g.139494093G>T	NM_005859.4:c.327G>T	p.(Glu109Asp)	class 3	Variant unclear	0.91	0.06
TRIO	Chr5(GRCh37):g.14374354G>A	NM_007118.3:c.3233G>A	p.(Arg1078Gln)	class 3	Variant unclear, clinician of opinion that phenotype fits	0.88	0.34
WAC	Chr10(GRCh37):g.28906631A>G	NM_016628.4(WAC):c.1792A>G	p.(Met598Val)	class 3	Variant unclear	0.82	0.29

464 References

- 465 [1] Vissers LELM, de Ligt J, Gilissen C, Janssen I, Steehouwer M, de Vries P, et al. A de novo
466 paradigm for mental retardation. *Nat Genet.* 2010 Dec;42(12):1109-12.
- 467 [2] de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, Kroes T, et al. Diag-
468 nostic exome sequencing in persons with severe intellectual disability. *N Engl J Med.* 2012
469 Nov;367(20):1921-9.
- 470 [3] Rauch A, Wiczorek D, Graf E, Wieland T, Ende S, Schwarzmayr T, et al. Range of genetic
471 mutations associated with severe non-syndromic sporadic intellectual disability: an exome
472 sequencing study. *Lancet.* 2012 Nov;380(9854):1674-82.
- 473 [4] Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BWM, Willemsen MH,
474 et al. Genome sequencing identifies major causes of severe intellectual disability. *Nature.*
475 2014 Jul;511(7509):344-7.
- 476 [5] Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for
477 the interpretation of sequence variants: a joint consensus recommendation of the American
478 College of Medical Genetics and Genomics and the Association for Molecular Pathology.
479 *Genet Med.* 2015 May;17(5):405-24.
- 480 [6] Beaumont RN, Wright CF. Estimating diagnostic noise in panel-based genomic analysis.
481 *Genet Med.* 2022 Aug.
- 482 [7] McGuire AL, Gabriel S, Tishkoff SA, Wonkam A, Chakravarti A, Furlong EEM, et al. The
483 road ahead in genetics and genomics. *Nat Rev Genet.* 2020 Oct;21(10):581-96.
- 484 [8] Logsdon GA, Vollger MR, Eichler EE. Long-read human genome sequencing and its appli-
485 cations. *Nat Rev Genet.* 2020 Oct;21(10):597-614.
- 486 [9] 100,000 Genomes Project Pilot Investigators, Smedley D, Smith KR, Martin A, Thomas EA,
487 McDonagh EM, et al. 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care -
488 Preliminary Report. *N Engl J Med.* 2021 Nov;385(20):1868-80.
- 489 [10] Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-
490 causing potential of sequence alterations. *Nat Methods.* 2010 Aug;7(8):575-6.
- 491 [11] Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method
492 and server for predicting damaging missense mutations. *Nat Methods.* 2010 Apr;7(4):248-9.
- 493 [12] Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on
494 protein function using the SIFT algorithm. *Nat Protoc.* 2009 Jun;4(7):1073-81.

- 495 [13] Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general frame-
496 work for estimating the relative pathogenicity of human genetic variants. *Nat Genet.* 2014
497 Mar;46(3):310-5.
- 498 [14] Robinson PN, Köhler S, Bauer S, Seelow D, Horn D, Mundlos S. The Human Phenotype
499 Ontology: a tool for annotating and analyzing human hereditary disease. *Am J Hum Genet.*
500 2008 Nov;83(5):610-5.
- 501 [15] Leite AJdC, Pinto IP, Leijsten N, Ruiterkamp-Versteeg M, Pfundt R, de Leeuw N, et al.
502 Diagnostic yield of patients with undiagnosed intellectual disability, global developmental
503 delay and multiples congenital anomalies using karyotype, microarray analysis, whole exome
504 sequencing from Central Brazil. *PLoS One.* 2022 Apr;17(4):e0266493.
- 505 [16] Clift K, Macklin S, Halverson C, McCormick JB, Dabrh AMA, Hines S. Patients’ views on
506 variants of uncertain significance across indications. *J Community Genet.* 2020;11(2):139-45.
- 507 [17] Makhnoon S, Garrett LT, Burke W, Bowen DJ, Shirts BH. Experiences of patients seeking to
508 participate in variant of uncertain significance reclassification research. *J Community Genet.*
509 2019 Apr;10(2):189-96.
- 510 [18] van Dijk S, Timmermans DRM, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W.
511 Clinical Characteristics Affect the Impact of an Uninformative DNA Test Result: The Course
512 of Worry and Distress Experienced by Women Who Apply for Genetic Testing for Breast
513 Cancer. *J Clin Oncol.* 2006;24(22):3672-7.
- 514 [19] Murray ML, Cerrato F, Bennett RL, Jarvik GP. Follow-up of carriers of BRCA1 and BRCA2
515 variants of unknown significance: variant reclassification and surgical decisions. *Genet Med.*
516 2011 Dec;13(12):998-1005.
- 517 [20] Hamburg MA, Collins FS. The path to personalized medicine. *N Engl J Med.* 2010
518 Jul;363(4):301-4.
- 519 [21] Ashley EA. Towards precision medicine. *Nat Rev Genet.* 2016 Aug;17(9):507-22.
- 520 [22] Brittain HK, Scott R, Thomas E. The rise of the genome and personalised medicine. *Clin*
521 *Med.* 2017 Dec;17(6):545-51.
- 522 [23] Coudray N, Ocampo PS, Sakellaropoulos T, Narula N, Snuderl M, Fenyö D, et al. Classifi-
523 cation and mutation prediction from non-small cell lung cancer histopathology images using
524 deep learning. *Nat Med.* 2018 Oct;24(10):1559-67.
- 525 [24] Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL. Artificial intelligence in
526 radiology. *Nat Rev Cancer.* 2018 Aug;18(8):500-10.

- 527 [25] Killock D. AI outperforms radiologists in mammographic screening. *Nat Rev Clin Oncol*.
528 2020 Mar;17(3):134.
- 529 [26] Lu MY, Chen TY, Williamson DFK, Zhao M, Shady M, Lipkova J, et al. AI-based pathology
530 predicts origins for cancers of unknown primary. *Nature*. 2021 Jun;594(7861):106-10.
- 531 [27] Poplin R, Chang PC, Alexander D, Schwartz S, Colthurst T, Ku A, et al. A universal SNP and
532 small-indel variant caller using deep neural networks. *Nat Biotechnol*. 2018 Nov;36(10):983-7.
- 533 [28] Sundaram L, Gao H, Padigepati SR, McRae JF, Li Y, Kosmicki JA, et al. Predicting the clin-
534 ical impact of human mutation with deep neural networks. *Nat Genet*. 2018 Aug;50(8):1161-
535 70.
- 536 [29] Wick RR, Judd LM, Holt KE. Performance of neural network basecalling tools for Oxford
537 Nanopore sequencing. *Genome Biol*. 2019 Jun;20(1):129.
- 538 [30] Köhler S, Schulz MH, Krawitz P, Bauer S, Dölken S, Ott CE, et al. Clinical diagnostics
539 in human genetics with semantic similarity searches in ontologies. *Am J Hum Genet*. 2009
540 Oct;85(4):457-64.
- 541 [31] Robinson PN, Köhler S, Oellrich A, Sanger Mouse Genetics Project, Wang K, Mungall
542 CJ, et al. Improved exome prioritization of disease genes through cross-species phenotype
543 comparison. *Genome Res*. 2014 Feb;24(2):340-8.
- 544 [32] Zemojtel T, Köhler S, Mackenroth L, Jäger M, Hecht J, Krawitz P, et al. Effective diagnosis
545 of genetic disease by computational phenotype analysis of the disease-associated genome. *Sci*
546 *Transl Med*. 2014 Sep;6(252):252ra123.
- 547 [33] Smedley D, Robinson PN. Phenotype-driven strategies for exome prioritization of human
548 Mendelian disease genes. *Genome Med*. 2015 Jul;7(1):81.
- 549 [34] Smedley D, Jacobsen JOB, Jäger M, Köhler S, Holtgrewe M, Schubach M, et al. Next-
550 generation diagnostics and disease-gene discovery with the Exomiser. *Nat Protoc*. 2015
551 Dec;10(12):2004-15.
- 552 [35] Hsieh TC, Mensah MA, Pantel JT, Aguilar D, Bar O, Bayat A, et al. PEDIA: prioritization
553 of exome data by image analysis. *Genet Med*. 2019 Dec;21(12):2807-14.
- 554 [36] Robinson PN, Ravanmehr V, Jacobsen JOB, Danis D, Zhang XA, Carmody LC, et al. In-
555 terpretable Clinical Genomics with a Likelihood Ratio Paradigm. *Am J Hum Genet*. 2020
556 Sep;107(3):403-17.

- 557 [37] Ferry Q, Steinberg J, Webber C, FitzPatrick DR, Ponting CP, Zisserman A, et al. Diagnos-
558 tically relevant facial gestalt information from ordinary photos. *Elife*. 2014 Jun;3:e02020.
- 559 [38] Dudding-Byth T, Baxter A, Holliday EG, Hackett A, O'Donnell S, White SM, et al. Com-
560 puter face-matching technology using two-dimensional photographs accurately matches the
561 facial gestalt of unrelated individuals with the same syndromic form of intellectual disability.
562 *BMC Biotechnol*. 2017 Dec;17(1):90.
- 563 [39] van der Donk R, Jansen S, Schuurs-Hoeijmakers JHM, Koolen DA, Goltstein LCMJ, Hoischen
564 A, et al. Next-generation phenotyping using computer vision algorithms in rare genomic
565 neurodevelopmental disorders. *Genet Med*. 2018 Dec.
- 566 [40] Gurovich Y, Hanani Y, Bar O, Nadav G, Fleischer N, Gelbman D, et al. Identifying facial
567 phenotypes of genetic disorders using deep learning. *Nat Med*. 2019 Jan;25(1):60-4.
- 568 [41] Dingemans AJM, Stremmelaar DE, van der Donk R, Vissers LELM, Koolen DA, Rump P,
569 et al. Quantitative facial phenotyping for Koolen-de Vries and 22q11.2 deletion syndrome.
570 *Eur J Hum Genet*. 2021 Feb;29(9):1418-23.
- 571 [42] Hsieh TC, Bar-Haim A, Moosa S, Ehmke N, Gripp KW, Pantel JT, et al. GestaltMatcher
572 facilitates rare disease matching using facial phenotype descriptors. *Nat Genet*. 2022 Feb.
- 573 [43] Claes P, Roosenboom J, White JD, Swigut T, Sero D, Li J, et al. Genome-wide mapping of
574 global-to-local genetic effects on human facial shape. *Nat Genet*. 2018 Mar;50(3):414-23.
- 575 [44] White JD, Indencleef K, Naqvi S, Eller RJ, Hoskens H, Roosenboom J, et al. Insights into
576 the genetic architecture of the human face. *Nat Genet*. 2021 Jan;53(1):45-53.
- 577 [45] Naqvi S, Sleyp Y, Hoskens H, Indencleef K, Spence JP, Bruffaerts R, et al. Shared heritability
578 of human face and brain shape. *Nat Genet*. 2021 Jun;53(6):830-9.
- 579 [46] Zhang M, Wu S, Du S, Qian W, Chen J, Qiao L, et al. Genetic variants underlying dif-
580 ferences in facial morphology in East Asian and European populations. *Nat Genet*. 2022
581 Apr;54(4):403-11.
- 582 [47] Vulto-van Silfhout AT, Hehir-Kwa JY, van Bon BWM, Schuurs-Hoeijmakers JHM, Meader S,
583 Hellebrekers CJM, et al. Clinical significance of de novo and inherited copy-number variation.
584 *Hum Mutat*. 2013 Dec;34(12):1679-87.
- 585 [48] Ribeiro MT, Singh S, Guestrin C. "Why should i trust you?" Explaining the predictions
586 of any classifier. In: *Proceedings of the 22nd ACM SIGKDD international conference on*
587 *knowledge discovery and data mining*; 2016. p. 1135-44.

- 588 [49] Ras G, Xie N, van Gerven M, Doran D. Explainable Deep Learning: A Field Guide for the
589 Uninitiated. *J Artif Intell Res.* 2022 Jan;73:329-96.
- 590 [50] Brier GW. Verification of forecasts expressed in terms of probability. *Mon Weather Rev.*
591 1950.
- 592 [51] Koolen DA, Kramer JM, Neveling K, Nillesen WM, Moore-Barton HL, Elmslie FV, et al. Mu-
593 tations in the chromatin modifier gene KANSL1 cause the 17q21.31 microdeletion syndrome.
594 *Nat Genet.* 2012 Apr;44(6):639-41.
- 595 [52] Zollino M, Orteschi D, Murdolo M, Lattante S, Battaglia D, Stefanini C, et al. Muta-
596 tions in KANSL1 cause the 17q21.31 microdeletion syndrome phenotype. *Nat Genet.* 2012
597 Apr;44(6):636-8.
- 598 [53] Koolen DA, DDD Study, Pfundt R, Linda K, Beunders G, Veenstra-Knol HE, et al. The
599 Koolen-de Vries syndrome: a phenotypic comparison of patients with a 17q21.31 microdele-
600 tion versus a KANSL1 sequence variant. *Eur J Hum Genet.* 2016;24(5):652-9.
- 601 [54] den Hoed J, de Boer E, Voisin N, Dingemans AJM, Guex N, Wiel L, et al. Mutation-specific
602 pathophysiological mechanisms define different neurodevelopmental disorders associated with
603 SATB1 dysfunction. *Am J Hum Genet.* 2021 Feb;108(2):346-56.
- 604 [55] Helmsmoortel C, Vulto-van Silfhout AT, Coe BP, Vandeweyer G, Rooms L, van den Ende J,
605 et al. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. *Nat*
606 *Genet.* 2014 Apr;46(4):380-4.
- 607 [56] Bend EG, Aref-Eshghi E, Everman DB, Rogers RC, Cathey SS, Prijoles EJ, et al. Gene
608 domain-specific DNA methylation epesignatures highlight distinct molecular entities of
609 ADNP syndrome. *Clin Epigenetics.* 2019 Apr;11(1):64.
- 610 [57] Breen MS, Garg P, Tang L, Mendonca D, Levy T, Barbosa M, et al. Epesignatures Stratifying
611 Helmsmoortel-Van Der Aa Syndrome Show Modest Correlation with Phenotype. *Am J Hum*
612 *Genet.* 2020 Sep;107(3):555-63.
- 613 [58] Jagadeesh KA, Birgmeier J, Guturu H, Deisseroth CA, Wenger AM, Bernstein JA, et al.
614 Phrank measures phenotype sets similarity to greatly improve Mendelian diagnostic disease
615 prioritization. *Genet Med.* 2019 Feb;21(2):464-70.
- 616 [59] Lyra PCM Jr, Nepomuceno TC, de Souza MLM, Machado GF, Veloso MF, Henriques TB,
617 et al. Integration of functional assay data results provides strong evidence for classification
618 of hundreds of BRCA1 variants of uncertain significance. *Genet Med.* 2021 Feb;23(2):306-15.

- 619 [60] Frederiksen JH, Jensen SB, Tümer Z, Hansen TVO. Classification of MSH6 Variants of
620 Uncertain Significance Using Functional Assays. *Int J Mol Sci*. 2021 Aug;22(16).
- 621 [61] Caswell RC, Gunning AC, Owens MM, Ellard S, Wright CF. Assessing the clinical utility
622 of protein structural analysis in genomic variant classification: experiences from a diagnostic
623 laboratory. *Genome Med*. 2022 Jul;14(1):77.
- 624 [62] Dingemans AJM, Stremmelaar DE, Vissers LELM, Jansen S, Nabais Sá MJ, van Remortele
625 A, et al. Human disease genes website series: An international, open and dynamic library
626 for up-to-date clinical information. *Am J Med Genet A*. 2021 Jan.
- 627 [63] McKusick VA. Mendelian Inheritance in Man and its online version, OMIM. *Am J Hum*
628 *Genet*. 2007 Apr;80(4):588-604.
- 629 [64] Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, et al. DECIPHER:
630 Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources.
631 *Am J Hum Genet*. 2009 Apr;84(4):524-33.
- 632 [65] Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al. GeneRe-
633 views®. Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al.,
634 editors. Seattle (WA): University of Washington, Seattle; 2010.
- 635 [66] Côté RA, Robboy S. Progress in medical information management. Systematized nomencla-
636 ture of medicine (SNOMED). *JAMA*. 1980;243(8):756-62.
- 637 [67] Parkhi OM, Vedaldi A, Zisserman A. Deep Face Recognition. *Proceedings of the British*
638 *Machine Vision Conference 2015*. 2015:41.1-41.12.
- 639 [68] Cao, Shen, Xie, Parkhi, Zisserman. VGGFace2: A Dataset for Recognising Faces across
640 Pose and Age. In: 2018 13th IEEE International Conference on Automatic Face & Gesture
641 Recognition (FG 2018). vol. 0; 2018. p. 67-74.
- 642 [69] Dingemans AJM, de Vries BBA, Vissers LEL, van Gerven MAJ, Hinne M. Comparing
643 facial feature extraction methods in the diagnosis of rare genetic syndromes. *medRxiv*. 2022
644 Aug;2022.08.26.22279217.
- 645 [70] Resnik P. Semantic Similarity in a Taxonomy: An Information-Based Measure and its
646 Application to Problems of Ambiguity in Natural Language. *J Artif Intell Res*. 1999 Jul;11:95-
647 130.
- 648 [71] Pesquita C, Faria D, Bastos H, Ferreira AEN, Falcão AO, Couto FM. Metrics for GO based
649 protein semantic similarity: a systematic evaluation. *BMC Bioinformatics*. 2008 Apr;9 Suppl
650 5:S4.

- 651 [72] Arvai, Kevin and Borroto, Carlos and Gainullin, Vladimir and Retterer, Kyle. Phenopy;
652 2019.
- 653 [73] Manders P, Lutomski JE, Smit C, Swinkels DW, Zielhuis GA. The Radboud biobank: A
654 central facility for disease-based biobanks to optimise use and distribution of biomaterial for
655 scientific research in the Radboud university medical center, Nijmegen. *Open J Bioresour.*
656 2018 Feb;5.
- 657 [74] Karras T, Laine S, Aila T. A Style-Based Generator Architecture for Generative Adversarial
658 Networks. *IEEE Trans Pattern Anal Mach Intell.* 2021 Dec;43(12):4217-28.
- 659 [75] Lopez-Paz D, Oquab M. Revisiting Classifier Two-Sample Tests. *arXiv.* 2016 Oct.
- 660 [76] Fisher RA. *Statistical methods for research workers* 12th edition. Oliver & Body; 1954.
- 661 [77] Rauch A, Zink S, Zweier C, Thiel CT, Koch A, Rauch R, et al. Systematic assessment of
662 atypical deletions reveals genotype-phenotype correlation in 22q11.2. *J Med Genet.* 2005
663 Nov;42(11):871-6.
- 664 [78] Brunet A, Gabau E, Perich RM, Valdesoiro L, Brun C, Caballín MR, et al. Microdele-
665 tion and microduplication 22q11.2 screening in 295 patients with clinical features of DiGe-
666 orge/Velocardiofacial syndrome. *Am J Med Genet A.* 2006 Nov;140(22):2426-32.
- 667 [79] Shprintzen RJ. Velo-cardio-facial syndrome: 30 Years of study. *Dev Disabil Res Rev.*
668 2008;14(1):3-10.
- 669 [80] Lipson AH, Yuille D, Angel M, Thompson PG, Vandervoord JG, Beckenham EJ. Velocardio-
670 facial (Shprintzen) syndrome: an important syndrome for the dysmorphologist to recognise.
671 *J Med Genet.* 1991 Sep;28(9):596-604.
- 672 [81] McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge
673 syndrome/velocardiofacial syndrome). *Medicine.* 2011 Jan;90(1):1-18.
- 674 [82] Grassi MS, Jacob CM, Kulikowski LD, Pastorino AC, Dutra RL, Miura N, et al. Congenital
675 Heart Disease as a Warning Sign for the Diagnosis of the 22q11.2 Deletion. *Arq Bras Cardiol.*
676 2014 Nov;103(5):382-90.
- 677 [83] Meinecke P, Beemer FA, Schinzel A, Kushnick T. The velo-cardio-facial (Shprintzen) syn-
678 drome. Clinical variability in eight patients. *Eur J Pediatr.* 1986 Dec;145(6):539-44.
- 679 [84] Bartsch O, Nemecková M, Kocárek E, Wagner A, Puchmajerová A, Poppe M, et al. DiGe-
680 orge/velocardiofacial syndrome: FISH studies of chromosomes 22q11 and 10p14, and clinical
681 reports on the proximal 22q11 deletion. *Am J Med Genet A.* 2003 Feb;117A(1):1-5.

- 682 [85] Marom R, Jain M, Burrage LC, Song IW, Graham BH, Brown CW, et al. Heterozygous vari-
683 ants in ACTL6A, encoding a component of the BAF complex, are associated with intellectual
684 disability. *Hum Mutat.* 2017 Oct;38(10):1365-71.
- 685 [86] Alazami AM, Hijazi H, Al-Dosari MS, Shaheen R, Hashem A, Aldahmesh MA, et al. Muta-
686 tion in ADAT3, encoding adenosine deaminase acting on transfer RNA, causes intellectual
687 disability and strabismus. *J Med Genet.* 2013 Jul;50(7):425-30.
- 688 [87] El-Hattab AW, Saleh MA, Hashem A, Al-Owain M, Asmari AA, Rabei H, et al. ADAT3-
689 related intellectual disability: Further delineation of the phenotype. *Am J Med Genet A.*
690 2016 May;170A(5):1142-7.
- 691 [88] Coe BP, Witherspoon K, Rosenfeld JA, van Bon BW, Vulto-van Silfhout AT, Bosco P,
692 et al. Refining analyses of copy number variation identifies specific genes associated with
693 developmental delay. *Nat Genet.* 2014 Oct;46(10):1063-71.
- 694 [89] Krajewska-Walasek M, Jurkiewicz D, Piekutowska-Abramczuk D, Kucharczyk M,
695 Chrzanowska KH, Jezela-Stanek A, et al. Additional data on the clinical phenotype of
696 Helsmoortel-Van der Aa syndrome associated with a novel truncating mutation in ADNP
697 gene. *Am J Med Genet A.* 2016 Jun;170(6):1647-50.
- 698 [90] Van Dijck A, Vulto-van Silfhout AT, Cappuyens E, van der Werf IM, Mancini GM, Tzschach
699 A, et al. Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by Mu-
700 tations in ADNP. *Biol Psychiatry.* 2019 Feb;85(4):287-97.
- 701 [91] Willemsen MH, Fernandez BA, Bacino CA, Gerkes E, de Brouwer AP, Pfundt R, et al.
702 Identification of ANKRD11 and ZNF778 as candidate genes for autism and variable cog-
703 nitive impairment in the novel 16q24.3 microdeletion syndrome. *Eur J Hum Genet.* 2010
704 Apr;18(4):429-35.
- 705 [92] Youngs EL, Hellings JA, Butler MG. ANKRD11 gene deletion in a 17-year-old male. *Clin*
706 *Dysmorphol.* 2011 Jul;20(3):170-1.
- 707 [93] Isrie M, Hendriks Y, Gielissen N, Sijstermans EA, Willemsen MH, Peeters H, et al. Haploin-
708 sufficiency of ANKRD11 causes mild cognitive impairment, short stature and minor dysmor-
709 phisms. *Eur J Hum Genet.* 2012 Feb;20(2):131-3.
- 710 [94] Sacharow S, Li D, Fan YS, Tekin M. Familial 16q24.3 microdeletion involving ANKRD11
711 causes a KBG-like syndrome. *Am J Med Genet A.* 2012 Mar;158A(3):547-52.

- 712 [95] Khalifa M, Stein J, Grau L, Nelson V, Meck J, Aradhya S, et al. Partial deletion of ANKRD11
713 results in the KBG phenotype distinct from the 16q24.3 microdeletion syndrome. *Am J Med*
714 *Genet A*. 2013 Apr;161A(4):835-40.
- 715 [96] Ockeloen CW, Willemsen MH, de Munnik S, van Bon BW, de Leeuw N, Verrips A, et al.
716 Further delineation of the KBG syndrome caused by ANKRD11 aberrations. *Eur J Hum*
717 *Genet*. 2015 Sep;23(9):1270.
- 718 [97] Nagamani SC, Erez A, Eng C, Ou Z, Chinault C, Workman L, et al. Interstitial deletion of
719 6q25.2-q25.3: a novel microdeletion syndrome associated with microcephaly, developmental
720 delay, dysmorphic features and hearing loss. *Eur J Hum Genet*. 2009 May;17(5):573-81.
- 721 [98] Hoyer J, Ekici AB, Ende S, Popp B, Zweier C, Wiesener A, et al. Haploinsufficiency of
722 ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause
723 of intellectual disability. *Am J Hum Genet*. 2012 Mar;90(3):565-72.
- 724 [99] Santen GWE, Aten E, Sun Y, Almomani R, Gilissen C, Nielsen M, et al. Mutations in
725 SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. *Nat*
726 *Genet*. 2012 Mar;44(4):379-80.
- 727 [100] Michelson M, Ben-Sasson A, Vinkler C, Leshinsky-Silver E, Netzer I, Frumkin A, et al. De-
728 lineation of the interstitial 6q25 microdeletion syndrome: refinement of the critical causative
729 region. *Am J Med Genet A*. 2012 Jun;158A(6):1395-9.
- 730 [101] Wieczorek D, Bögershausen N, Beleggia F, Steiner-Haldenstädt S, Pohl E, Li Y, et al. A
731 comprehensive molecular study on Coffin-Siris and Nicolaides-Baraitser syndromes identifies
732 a broad molecular and clinical spectrum converging on altered chromatin remodeling. *Hum*
733 *Mol Genet*. 2013 Dec;22(25):5121-35.
- 734 [102] Vals MA, Öglane-Shlik E, Nöukas M, Shor R, Peet A, Kals M, et al. Coffin-Siris Syndrome
735 with obesity, macrocephaly, hepatomegaly and hyperinsulinism caused by a mutation in the
736 ARID1B gene. *Eur J Hum Genet*. 2014 Nov;22(11):1327-9.
- 737 [103] Ben-Salem S, Sobreira N, Akawi NA, Al-Shamsi AM, John A, Pramathan T, et al. Gonadal
738 mosaicism in ARID1B gene causes intellectual disability and dysmorphic features in three
739 siblings. *Am J Med Genet A*. 2016 Jan;170A(1):156-61.
- 740 [104] Ronzoni L, Tagliaferri F, Tucci A, Baccarin M, Esposito S, Milani D. Interstitial 6q25 mi-
741 crodeletion syndrome: ARID1B is the key gene. *Am J Med Genet A*. 2016 May;170A(5):1257-
742 61.

- 743 [105] Gripp KW, Baker L, Telegrafi A, Monaghan KG. The role of objective facial analysis using
744 FDNA in making diagnoses following whole exome analysis. Report of two patients with
745 mutations in the BAF complex genes. *Am J Med Genet A*. 2016 Jul;170(7):1754-62.
- 746 [106] Zweier M, Peippo MM, Pöyhönen M, Kääriäinen H, Begemann A, Joset P, et al. The
747 HHID syndrome of hypertrichosis, hyperkeratosis, abnormal corpus callosum, intellectual
748 disability, and minor anomalies is caused by mutations in ARID1B. *Am J Med Genet A*.
749 2017 May;173(5):1440-3.
- 750 [107] Määttänen L, Hietala M, Ignatius J, Arvio M. A 69-year-old woman with Coffin-Siris syn-
751 drome. *Am J Med Genet A*. 2018 Aug;176(8):1764-7.
- 752 [108] van der Sluijs PJ, Jansen S, Vergano SA, Adachi-Fukuda M, Alanay Y, AlKindy A, et al. The
753 ARID1B spectrum in 143 patients: from nonsyndromic intellectual disability to Coffin-Siris
754 syndrome. *Genet Med*. 2019 Jun;21(6):1295-307.
- 755 [109] Liu X, Hu G, Ye J, Ye B, Shen N, Tao Y, et al. De Novo ARID1B mutations cause growth
756 delay associated with aberrant Wnt/ β -catenin signaling. *Hum Mutat*. 2020 May;41(5):1012-
757 24.
- 758 [110] Lian S, Ting TW, Lai AHM, Tan ES, Wei H, Cham B, et al. Coffin-Siris Syndrome-1:
759 Report of five cases from Asian populations with truncating mutations in the ARID1B gene.
760 *J Neurol Sci*. 2020 Jul;414:116819.
- 761 [111] Snijders Blok L, Rousseau J, Twist J, Ehresmann S, Takaku M, Venselaar H, et al. CHD3
762 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and
763 impaired speech and language. *Nat Commun*. 2018 Nov;9(1):4619.
- 764 [112] Drivas TG, Li D, Nair D, Alaimo JT, Alders M, Altmüller J, et al. A second cohort of
765 CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau
766 syndrome. *Eur J Hum Genet*. 2020 Oct;28(10):1422-31.
- 767 [113] O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, et al. Multiplex targeted
768 sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science*. 2012
769 Dec;338(6114):1619-22.
- 770 [114] Bernier R, Golzio C, Xiong B, Stessman HA, Coe BP, Penn O, et al. Disruptive CHD8
771 mutations define a subtype of autism early in development. *Cell*. 2014 Jul;158(2):263-76.
- 772 [115] Douzgou S, Liang HW, Metcalfe K, Somarathi S, Tischkowitz M, Mohamed W, et al. The
773 clinical presentation caused by truncating CHD8 variants. *Clin Genet*. 2019 Jul;96(1):72-84.

- 774 [116] Ostrowski PJ, Zachariou A, Loveday C, Beleza-Meireles A, Bertoli M, Dean J, et al. The
775 CHD8 overgrowth syndrome: A detailed evaluation of an emerging overgrowth phenotype in
776 27 patients. *Am J Med Genet C Semin Med Genet.* 2019 Dec;181(4):557-64.
- 777 [117] Snijders Blok L, Madsen E, Juusola J, Gilissen C, Baralle D, Reijnders MR, et al. Mutations
778 in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific
779 Effects on Wnt Signaling. *Am J Hum Genet.* 2015 Aug;97(2):343-52.
- 780 [118] Møller RS, Kübart S, Hoeltzenbein M, Heye B, Vogel I, Hansen CP, et al. Truncation of the
781 Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. *Am*
782 *J Hum Genet.* 2008 May;82(5):1165-70.
- 783 [119] van Bon BW, Hoischen A, Hehir-Kwa J, de Brouwer AP, Ruivenkamp C, Gijsbers AC, et al.
784 Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly. *Clin*
785 *Genet.* 2011 Mar;79(3):296-9.
- 786 [120] Courcet JB, Faivre L, Malzac P, Masurel-Paulet A, Lopez E, Callier P, et al. The DYRK1A
787 gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy. *J*
788 *Med Genet.* 2012 Dec;49(12):731-6.
- 789 [121] van Bon BW, Coe BP, Bernier R, Green C, Gerdtts J, Witherspoon K, et al. Disruptive de
790 novo mutations of DYRK1A lead to a syndromic form of autism and ID. *Mol Psychiatry.*
791 2016 Jan;21(1):126-32.
- 792 [122] Willemsen MH, Vulto-van Silfhout AT, Nillesen WM, Wissink-Lindhout WM, van Bokhoven
793 H, Philip N, et al. Update on Kleefstra Syndrome. *Mol Syndromol.* 2012 Apr;2(3-5):202-12.
- 794 [123] Lelieveld SH, Reijnders MR, Pfundt R, Yntema HG, Kamsteeg EJ, de Vries P, et al. Meta-
795 analysis of 2,104 trios provides support for 10 new genes for intellectual disability. *Nat*
796 *Neurosci.* 2016 Sep;19(9):1194-6.
- 797 [124] Jansen S, Geuer S, Pfundt R, Brough R, Ghongane P, Herkert JC, et al. De Novo Truncating
798 Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability
799 Syndrome. *Am J Hum Genet.* 2017 Apr;100(4):650-8.
- 800 [125] Koolen DA, Vissers LEL, Pfundt R, de Leeuw N, Knight SJL, Regan R, et al. A new chromo-
801 some 17q21.31 microdeletion syndrome associated with a common inversion polymorphism.
802 *Nat Genet.* 2006;38(9):999-1001.
- 803 [126] Hoyer J, Dreweke A, Becker C, Göhring I, Thiel CT, Peippo MM, et al. Molecular karyotyping
804 in patients with mental retardation using 100K single-nucleotide polymorphism arrays. *J Med*
805 *Genet.* 2007 Oct;44(10):629-36.

- 806 [127] Koolen DA, Sharp AJ, Hurst JA, Firth HV, Knight SJL, Goldenberg A, et al. Clinical
807 and molecular delineation of the 17q21.31 microdeletion syndrome. *J Med Genet.* 2008
808 Nov;45(11):710-20.
- 809 [128] Dubourg C, Sanlaville D, Doco-Fenzy M, Le Caignec C, Missirian C, Jaillard S, et al. Clinical
810 and molecular characterization of 17q21.31 microdeletion syndrome in 14 French patients
811 with mental retardation. *Eur J Med Genet.* 2011 Mar;54(2):144-51.
- 812 [129] Diets IJ, van der Donk R, Baltrunaite K, Waanders E, Reijnders MRF, Dingemans AJM,
813 et al. De Novo and Inherited Pathogenic Variants in KDM3B Cause Intellectual Disability,
814 Short Stature, and Facial Dysmorphism. *Am J Hum Genet.* 2019 Apr;104(4):758-66.
- 815 [130] Clayton-Smith J, Walters S, Hobson E, Burkitt-Wright E, Smith R, Toutain A, et al. Xq28
816 duplication presenting with intestinal and bladder dysfunction and a distinctive facial ap-
817 pearance. *Eur J Hum Genet.* 2009 Apr;17(4):434-43.
- 818 [131] Lugtenberg D, Kleefstra T, Oudakker AR, Nillesen WM, Yntema HG, Tzschach A, et al.
819 Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained
820 XLMR and in 2% of male patients with severe encephalopathy. *Eur J Hum Genet.* 2009
821 Apr;17(4):444-53.
- 822 [132] Asadollahi R, Oneda B, Sheth F, Azzarello-Burri S, Baldinger R, Joset P, et al. Dosage
823 changes of MED13L further delineate its role in congenital heart defects and intellectual
824 disability. *Eur J Hum Genet.* 2013 Oct;21(10):1100-4.
- 825 [133] van Haelst MM, Monroe GR, Duran K, van Binsbergen E, Breur JM, Giltay JC, et al.
826 Further confirmation of the MED13L haploinsufficiency syndrome. *Eur J Hum Genet.* 2015
827 Jan;23(1):135-8.
- 828 [134] Cafiero C, Marangi G, Orteschi D, Ali M, Asaro A, Ponzi E, et al. Novel de novo heterozy-
829 gous loss-of-function variants in MED13L and further delineation of the MED13L haploin-
830 sufficiency syndrome. *Eur J Hum Genet.* 2015 Nov;23(11):1499-504.
- 831 [135] Asadollahi R, Zweier M, Gogoll L, Schiffmann R, Sticht H, Steindl K, et al. Genotype-
832 phenotype evaluation of MED13L defects in the light of a novel truncating and a recurrent
833 missense mutation. *Eur J Med Genet.* 2017 Sep;60(9):451-64.
- 834 [136] Smol T, Petit F, Piton A, Keren B, Sanlaville D, Afenjar A, et al. MED13L-related in-
835 tellectual disability: involvement of missense variants and delineation of the phenotype.
836 *Neurogenetics.* 2018 May;19(2):93-103.

- 837 [137] Tørring PM, Larsen MJ, Brasch-Andersen C, Krogh LN, Kibæk M, Laulund L, et al. Is
838 MED13L-related intellectual disability a recognizable syndrome? *Eur J Med Genet.* 2019
839 Feb;62(2):129-36.
- 840 [138] Schuurs-Hoeijmakers JH, Landsverk ML, Foulds N, Kukolich MK, Gavrilova RH, Greville-
841 Heygate S, et al. Clinical delineation of the PACS1-related syndrome—Report on 19 patients.
842 *Am J Med Genet A.* 2016 Mar;170(3):670-5.
- 843 [139] Jansen S, Hoischen A, Coe BP, Carvill GL, Van Esch H, Bosch DGM, et al. A genotype-first
844 approach identifies an intellectual disability-overweight syndrome caused by PHIP haploin-
845 sufficiency. *Eur J Hum Genet.* 2018 Jan;26(1):54-63.
- 846 [140] Tanaka AJ, Bai R, Cho MT, Anyane-Yeboa K, Ahimaz P, Wilson AL, et al. De novo
847 mutations in PURA are associated with hypotonia and developmental delay. *Cold Spring*
848 *Harb Mol Case Stud.* 2015 Oct;1(1):a000356.
- 849 [141] Reijnders MRF, Janowski R, Alvi M, Self JE, van Essen TJ, Vreeburg M, et al. PURA
850 syndrome: clinical delineation and genotype-phenotype study in 32 individuals with review
851 of published literature. *J Med Genet.* 2018 Feb;55(2):104-13.
- 852 [142] Lee BH, Reijnders MRF, Abubakare O, Tuttle E, Lape B, Minks KQ, et al. Expanding the
853 neurodevelopmental phenotype of PURA syndrome. *Am J Med Genet A.* 2018 Jan;176(1):56-
854 67.
- 855 [143] Takenouchi T, Miura K, Uehara T, Mizuno S, Kosaki K. Establishing SON in 21q22.11 as
856 a cause a new syndromic form of intellectual disability: Possible contribution to Braddock-
857 Carey syndrome phenotype. *Am J Med Genet A.* 2016 Oct;170(10):2587-90.
- 858 [144] Kim JH, Shinde DN, Reijnders MRF, Hauser NS, Belmonte RL, Wilson GR, et al. De
859 Novo Mutations in SON Disrupt RNA Splicing of Genes Essential for Brain Development
860 and Metabolism, Causing an Intellectual-Disability Syndrome. *Am J Hum Genet.* 2016
861 Sep;99(3):711-9.
- 862 [145] Dingemans AJM, Truijien KMG, Kim JH, Alaçam Z, Faivre L, Collins KM, et al. Establishing
863 the phenotypic spectrum of ZTTK syndrome by analysis of 52 individuals with variants in
864 SON. *Eur J Hum Genet.* 2021 Sep.
- 865 [146] Ba W, Yan Y, Reijnders MR, Schuurs-Hoeijmakers JH, Feenstra I, Bongers EM, et al. TRIO
866 loss of function is associated with mild intellectual disability and affects dendritic branching
867 and synapse function. *Hum Mol Genet.* 2016 Mar;25(5):892-902.

- 868 [147] Pengelly RJ, Greville-Heygate S, Schmidt S, Seaby EG, Jabalameli MR, Mehta SG, et al.
869 Mutations specific to the Rac-GEF domain of TRIO cause intellectual disability and micro-
870 cephal. *J Med Genet.* 2016 Nov;53(11):735-42.
- 871 [148] DeSanto C, D'Aco K, Araujo GC, Shannon N, Vernon H, Rahrig A, et al. WAC loss-
872 of-function mutations cause a recognisable syndrome characterised by dysmorphic features,
873 developmental delay and hypotonia and recapitulate 10p11.23 microdeletion syndrome. *J*
874 *Med Genet.* 2015 Nov;52(11):754-61.
- 875 [149] Lugtenberg D, Reijnders MR, Fenckova M, Bijlsma EK, Bernier R, van Bon BW, et al. De
876 novo loss-of-function mutations in WAC cause a recognizable intellectual disability syndrome
877 and learning deficits in *Drosophila*. *Eur J Hum Genet.* 2016 Aug;24(8):1145-53.
- 878 [150] Gabriele M, Vulto-van Silfhout AT, Germain PL, Vitriolo A, Kumar R, Douglas E, et al. YY1
879 Haploinsufficiency Causes an Intellectual Disability Syndrome Featuring Transcriptional and
880 Chromatin Dysfunction. *Am J Hum Genet.* 2017 Jun;100(6):907-25.